"Idogen recently signed a collaboration agreement for production with the Radboud University Medical Center in the Netherlands, a global leader in the field with 20 years of experience in manufacturing cell therapy. The agreement is a step forward in Idogen"s journey in bringing its pipeline projects, IDO 8 and IDO T, towards clinical trials (expected to commence in Q1 2021).

During the third quarter, the cost development remained healthy and Idogen reiterated its expectation that its end-of-quarter cash position of SEK 33.8m is sufficient to finance operations until Q3 2020."

Länk till uppdragsanalys nedan.

Länk till analysen